Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) finished Wednesday with a subtraction of $0.0 to close at $0.56, an upside of 1.22 percent. An average of 12,609,221 shares of common stock have been traded in the last five days. There was a gain of $0.0283 in the past week. The last 20 days have seen an average of 13,568,391 shares traded, while the 50-day average volume stands at 12,412,712.
TNXP stock has decreased by -8.46% in the last month. The company shares reached their 1-month lowest point of $0.5200 on 10/12/21. With the stock rallying to its 52-week high on 02/11/21, shares of the company touched a low of $0.51 and a high of $2.12 in 52 weeks. In spite of this, the price is down -73.47% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Tonix Pharmaceuticals Holding Corp. (TNXP) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 1.18. Other valuation ratios to consider include the price-to-book (PB) ratio at 1.04.
The quick ratio of Tonix Pharmaceuticals Holding Corp. for the three months ended June 29 was 21.90, and the current ratio was 21.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Tonix Pharmaceuticals Holding Corp.’s return on assets was -54.40%, compared to -107.5% over the last five years. Meanwhile, the return on equity (ROE) for the past 12 months has been -57.70% and the 5-year average holds at -124.0%. For the broader industry, ROE averaged -68.79 over the past year.
The analyst consensus anticipated Tonix Pharmaceuticals Holding Corp.’s latest quarter earnings to come in at -$0.06 per share, but it turned out to be -$0.07, a -16.70% surprise. Shareholders own equity worth $357.52 million.
From a technical analysis perspective, let’s take a brief look at Tonix Pharmaceuticals Holding Corp. (TNXP) price momentum. RSI 9-day as of the close on 13 October was 45.05%, suggesting the stock is Neutral, with historical volatility in this time frame at 54.61%.
As of today, TNXP’s price is $0.5418 +5.30% or $0.0283 from its 5-day moving average. TNXP is currently trading -9.38% lower than its 20-day SMA and -50.23% lower than its 100-day SMA. However, the stock’s current price level is -18.80% below the SMA50 and -19.43% below the SMA200.
The stochastic %K and %D were 22.64% and 13.21%, respectively, and the average true range (ATR) was 0.0304. With the 14-day stochastic at 36.87% and the average true range at 0.0328, the RSI (14) stands at 41.19%. The stock has reached -0.0067 on the 9-day MACD Oscillator while the 14-day reading was at -0.0230.
ROTH Capital upgraded Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a a Neutral.The consensus rating for Tonix Pharmaceuticals Holding Corp. (TNXP) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TNXP, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is TNXP’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $3.00, with a median target of $3.00. Taking a look at these predictions, the average price target given by analysts for Tonix Pharmaceuticals Holding Corp. (TNXP) stock is $3.00.